Back to main

Lilly's Cyramza Misses Primary Goal in Liver Cancer Study

By Tess Stynes

Eli Lilly & Co. (LLY) said its Cyramza cancer drug failed to meet primary goals in a Phase III study of the drug as a secondary treatment for patients with liver cancer.

The drug maker said overall survival data favored patients who received Cyramza, also known as ramucirumab, over a placebo. However, the difference wasn't statistically significant.

While the study didn't "achieve statistical significance for survival, we are encouraged by the efficacy seen overall, especially in specific subpopulations," said Richard Gaynor, senior vice president, product development and medical affairs for Lilly Oncology.

"We plan to discuss these results with regulatory authorities," he added.

Lilly has been focusing on advancing and replenishing its drug pipeline as key drugs lose market exclusivity.

Cyramza was granted orphan-drug status by the U.S. Food and Drug Administration and European regulators.

Lilly gained Cyramza through its 2008 acquisition of ImClone Systems. The drug is being investigated in clinical trials as a single agent and in combination with other anti-cancer therapies for the treatment of multiple tumor types.

Cyramza has U.S. approval for hard-to-treat cases of advanced gastric cancer.

Write to Tess Stynes at

Subscribe to WSJ:

  (END) Dow Jones Newswires
  Copyright (c) 2014 Dow Jones & Company, Inc.